|
<< Prev
26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 Next >> |
|
Complete Response for Akebia Vadadustat
[2692 Words]
[ Price : $8.95]
|
FDA issues a complete response letter for Akebia’s vadadustat citing a negative benefit/risk assessment and safety concerns. |
03/30/2022
|
|
|
|
Panel Votes 6 to 4 to Reject Amylyx ALS Drug
[488 Words]
[ Price : $8.95]
|
FDA’s Peripheral and Central Nervous System Drugs Advisory Committee votes 6 to 4 that data from a single randomized, controlled trial and an open-label extension study did not establish that Amylyx Pharmaceuticals’ AMX0035S therapy is effective in treating ALS patients. |
03/30/2022
|
|
|
|
|
FDA Provides More Details on Legislative Proposals
[855 Words]
[ Price : $8.95]
|
FDA releases an executive summary that provides more details on the package of legislative proposals that were included in the agency’s FY 2023 budget proposal for the agency, including expanded authority to enhance remote regulatory assessments that were widely used during the Covid-19 pandemic and more authority to ensure medical device firms implement cybersecurity protections. |
03/29/2022
|
|
|
|
CISA Philips e-Alert Advisory
[2644 Words]
[ Price : $8.95]
|
The federal Cybersecurity & Infrastructure Security Agency identifies a vulnerability in the Philips e-Alert MRI monitoring platform. |
03/29/2022
|
|
|
|
|
CGMP Issues at Agropharma Laboratories
[2826 Words]
[ Price : $8.95]
|
FDA warns Salinas, Puerto Rico-based Agropharma Laboratories about repeat CGMP violations in its production of finished drugs. |
03/29/2022
|
|
|
|
|
Dr Retter CGMP Violations Cited
[2858 Words]
[ Price : $8.95]
|
FDA warns Mazowieckie, Poland-based Dr Retter Ec Wladyslaw Retter about CGMP violations in its production of over-the-counter drugs. |
03/29/2022
|
|
|
|
|
<< Prev
26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 Next >> |
|